메뉴 건너뛰기




Volumn 24, Issue 1, 2013, Pages 10-14

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: A randomized controlled clinical trial

Author keywords

Azithromycin; Dyspepsia; Helicobacter pylori; Rapid urease test; Urease breath test

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; OMEPRAZOLE;

EID: 84879676490     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2013.0540     Document Type: Article
Times cited : (11)

References (41)
  • 1
    • 0036791678 scopus 로고    scopus 로고
    • Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori
    • Sullivan B, Coyle W, Nemec R, Dunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002;97:2536-9.
    • (2002) Am J Gastroenterol , vol.97 , pp. 2536-2539
    • Sullivan, B.1    Coyle, W.2    Nemec, R.3    Dunteman, T.4
  • 2
    • 0034790520 scopus 로고    scopus 로고
    • Helicobacter pylori: Ulcers and more: The beginning of an era
    • Lacy BE, Rosemore J. Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 2001;131:2789S-93S.
    • (2001) J Nutr , vol.131
    • Lacy, B.E.1    Rosemore, J.2
  • 3
    • 0038235692 scopus 로고    scopus 로고
    • The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study [Published correction appears in Aliment Pharmacol Ther 2004; 20:702]
    • Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study [Published correction appears in Aliment Pharmacol Ther 2004;20:702]. Aliment Pharmacol Ther 2003;17:1481-91.
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 1481-1491
    • Thomson, A.B.1    Barkun, A.N.2    Armstrong, D.3
  • 4
    • 0033807944 scopus 로고    scopus 로고
    • Recent developments in the epidemiology of Helicobacter pylori
    • Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000;29: 559-78.
    • (2000) Gastroenterol Clin North Am , vol.29 , pp. 559-578
    • Everhart, J.E.1
  • 5
    • 0033664804 scopus 로고    scopus 로고
    • Helicobacter pylori infection in children: Recommendations for diagnosis and treatment
    • and North American Society for Pediatric Gastroenterology and Nutrition
    • Gold BD, Colletti RB, Abbott M, et al and North American Society for Pediatric Gastroenterology and Nutrition. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
    • (2000) J Pediatr Gastroenterol Nutr , vol.31 , pp. 490-497
    • Gold, B.D.1    Colletti, R.B.2    Abbott, M.3
  • 6
    • 0029907820 scopus 로고    scopus 로고
    • A population-based serologic survey of Helicobacter pylori infection in children and adolescents in the United States
    • Staat MA, Kruszon-Moran D, McQuillan GM, Kaslow RA. A population-based serologic survey of Helicobacter pylori infection in children and adolescents in the United States. J Infect Dis 1996;174:1120-3.
    • (1996) J Infect Dis , vol.174 , pp. 1120-1123
    • Staat, M.A.1    Kruszon-Moran, D.2    McQuillan, G.M.3    Kaslow, R.A.4
  • 7
    • 0029816488 scopus 로고    scopus 로고
    • Pooled analysis of anti-Helicobacter pylori treatment regimens
    • Unge P, Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroentrol Suppl. 1996;220:27-40.
    • (1996) Scand J Gastroentrol Suppl , vol.220 , pp. 27-40
    • Unge, P.1    Berstad, A.2
  • 8
    • 0036310272 scopus 로고    scopus 로고
    • Role of Helicobacter pylori in gastric carcinogenesis
    • Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am 2002;31:517-35.
    • (2002) Gastroenterol Clin North Am , vol.31 , pp. 517-535
    • Sepulveda, A.R.1    Graham, D.Y.2
  • 9
    • 7044247643 scopus 로고    scopus 로고
    • Will eradication of Helicobacter pylori infection influence the risk of gastric cancer?
    • Hunt RH. Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Am J Med 2004;117 (Suppl 5A):86S-91S.
    • (2004) Am J Med , vol.117 , Issue.SUPPL. 5A
    • Hunt, R.H.1
  • 10
    • 84921703317 scopus 로고    scopus 로고
    • H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer
    • Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;CD004062
    • (2004) Cochrane Database Syst Rev
    • Gisbert, J.P.1    Khorrami, S.2    Carballo, F.3
  • 11
    • 4544263657 scopus 로고    scopus 로고
    • Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis
    • Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
    • (2004) Am J Gastroenterol , vol.99 , pp. 1833-1855
    • Ford, A.C.1    Delaney, B.C.2    Forman, D.3    Moayyedi, P.4
  • 13
    • 4043124586 scopus 로고    scopus 로고
    • Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of the Helicobacter pylori in patients with peptic ulcer
    • Coelho LGV, Mattos AA, Francisconi CFM, et al. Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of the Helicobacter pylori in patients with peptic ulcer. Arq Gastroenterol. 2004;41: 71-6.
    • (2004) Arq Gastroenterol , vol.41 , pp. 71-76
    • Lgv, C.1    Mattos, A.A.2    Cfm, F.3
  • 14
    • 12244295761 scopus 로고    scopus 로고
    • Low Helicobacter pylori eradication rates with 4-and 7-day regimens in an Iranian population
    • Malekzadeh R, Merat S, Derakhshan MH, et al. Low Helicobacter pylori eradication rates with 4-and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003;18:13-7.
    • (2003) J Gastroenterol Hepatol , vol.18 , pp. 13-17
    • Malekzadeh, R.1    Merat, S.2    Derakhshan, M.H.3
  • 15
    • 60749100786 scopus 로고    scopus 로고
    • Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen
    • Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
    • (2009) Am J Gastroenterol , vol.104 , pp. 21-25
    • Rokkas, T.1    Sechopoulos, P.2    Robotis, I.3
  • 16
    • 0033788930 scopus 로고    scopus 로고
    • Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: A metanalysis of eradication of Helicobacter pylori
    • Gisbert JP, Gonzales L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a metanalysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-28.
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 1319-1328
    • Gisbert, J.P.1    Gonzales, L.2    Calvet, X.3
  • 17
  • 18
    • 0025162303 scopus 로고
    • In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria
    • Kitzis MD, Goldstein FW, Miégi M, Acar JF. In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother 1990;25 Suppl A:15-18.
    • (1990) J Antimicrob Chemother , vol.25 , Issue.SUPPL. A , pp. 15-18
    • Kitzis, M.D.1    Goldstein, F.W.2    Miégi, M.3    Acar, J.F.4
  • 20
    • 23744506840 scopus 로고    scopus 로고
    • Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: An open randomized clinical trial
    • Frota LC, da Cunha Mdo P, Luz CR, de Araujo-Filho AH. Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial. Arq Gastroenterol 2005;42:111-5.
    • (2005) Arq Gastroenterol , vol.42 , pp. 111-115
    • Frota, L.C.1    Da Cunha Mdo, P.2    Luz, C.R.3    De Araujo-Filho, A.H.4
  • 21
    • 0036791611 scopus 로고    scopus 로고
    • Azithromycin in a triple therapy for H. pylori eradication in active duodenal ulcer
    • Ivashkin VT, Lapina TL, Bondarenko OY, et al. Azithromycin in a triple therapy for H. pylori eradication in active duodenal ulcer. World J Gastroenterol 2002;8:879-92.
    • (2002) World J Gastroenterol , vol.8 , pp. 879-892
    • Ivashkin, V.T.1    Lapina, T.L.2    Bondarenko, O.Y.3
  • 22
    • 0030223132 scopus 로고    scopus 로고
    • Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials
    • Lind T, Veldhuyzen Van Zenten S, Unge P, et al. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials. The MACH 1 study. Helicobacter 1996;1:138-44.
    • (1996) The MACH 1 Study. Helicobacter , vol.1 , pp. 138-144
    • Lind, T.1    Veldhuyzen Van Zenten, S.2    Unge, P.3
  • 23
    • 0032990642 scopus 로고    scopus 로고
    • Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citratebased triple therapy
    • Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citratebased triple therapy. Aliment Pharmacol Ther 1999;13: 163-8.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 163-168
    • Rinaldi, V.1    Zullo, A.2    De Francesco, V.3
  • 24
    • 0007522959 scopus 로고    scopus 로고
    • The MACH 2 study: Eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy
    • Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The MACH 2 study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999;13:289-95.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 289-295
    • Van Zanten Sjo, V.1    Bradette, M.2    Farley, A.3
  • 26
    • 68849113749 scopus 로고    scopus 로고
    • Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment
    • Songür Y, fienol A, Balkarli A, et al. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009; 338:50-3.
    • (2009) Am J Med Sci , vol.338 , pp. 50-53
    • Songür, Y.1    Fienol, A.2    Balkarli, A.3
  • 27
    • 0036534963 scopus 로고    scopus 로고
    • Management of Helicobacter pylori infection
    • Meurer LN, Bower DJ. Management of Helicobacter pylori infection. Am Fam Physician 2002;65:1327-36.
    • (2002) Am Fam Physician , vol.65 , pp. 1327-1336
    • Meurer, L.N.1    Bower, D.J.2
  • 28
    • 0141676717 scopus 로고    scopus 로고
    • One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection
    • Lara LF, Cisneros G, Gurney M, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003;163:2079-84.
    • (2003) Arch Intern Med , vol.163 , pp. 2079-2084
    • Lara, L.F.1    Cisneros, G.2    Gurney, M.3
  • 29
    • 0037185531 scopus 로고    scopus 로고
    • Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: A randomized controlled trial (MACLOR study)
    • Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.
    • (2002) Arch Intern Med , vol.162 , pp. 153-160
    • Treiber, G.1    Wittig, J.2    Ammon, S.3
  • 30
    • 0029942448 scopus 로고    scopus 로고
    • In-vitro active of azitromycin against intracellular Helicobacter pylori
    • Hulten K, Cars O, Hjelm E, Engstrand L. In-vitro active of azitromycin against intracellular Helicobacter pylori. J Antimicrob Chemother 1996;37:483-9.
    • (1996) J Antimicrob Chemother , vol.37 , pp. 483-489
    • Hulten, K.1    Cars, O.2    Hjelm, E.3    Engstrand, L.4
  • 31
    • 0031673838 scopus 로고    scopus 로고
    • Low-versus high-dose azithromycin triple therapy for Helicobacter pylori infection
    • Chey WD, Fisher L, Barnett J, et al. Low-versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:1263-7.
    • (1998) Aliment Pharmacol Ther , vol.12 , pp. 1263-1267
    • Chey, W.D.1    Fisher, L.2    Barnett, J.3
  • 32
    • 0028900902 scopus 로고
    • Azithromycin triple therapy for Helicobacter pylori infection: Azithromycin, tetracycline, and bismuth
    • al-Assi MT, Genta RM, Karttunen TJ, et al. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol 1995; 90:403-5.
    • (1995) Am J Gastroenterol , vol.90 , pp. 403-405
    • Al-Assi, M.T.1    Genta, R.M.2    Karttunen, T.J.3
  • 33
    • 0030027591 scopus 로고    scopus 로고
    • Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: A controlled trial versus omeprazole plus amoxicillin
    • Bertoni G, Sassatelli R, Nigrisoli E, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996;91:258-63
    • (1996) Am J Gastroenterol , vol.91 , pp. 258-263
    • Bertoni, G.1    Sassatelli, R.2    Nigrisoli, E.3
  • 34
    • 33645194533 scopus 로고    scopus 로고
    • Azithromycin, furazolidone and omeprazole: A promising low-dose, low-cost, short-term anti H. pylori triple therapy [abstract]
    • Coelho LGV, Vieira WLS, Passos MCF. Azithromycin, furazolidone and omeprazole: a promising low-dose, low-cost, short-term anti H. pylori triple therapy [abstract]. Gastroenterology 1998;1196:296.
    • (1998) Gastroenterology , vol.1196 , pp. 296
    • Lgv, C.1    Wls, V.2    McF, P.3
  • 35
    • 0033000867 scopus 로고    scopus 로고
    • Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection
    • Liu WZ, Xiao, SD, Shi Y, et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1999:13:317-22.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 317-322
    • Liu, W.Z.1    Xiao, S.D.2    Shi, Y.3
  • 36
    • 0034094599 scopus 로고    scopus 로고
    • A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection
    • Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9.
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 603-609
    • Calvet, X.1    Garcia, N.2    Lopez, T.3
  • 37
    • 2442715467 scopus 로고    scopus 로고
    • Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection
    • Gribajceviæ M, Vanis N, Mesihoviæ R. Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection. Med Arh 2003;57:107-10.
    • (2003) Med Arh , vol.57 , pp. 107-110
    • Gribajceviæ, M.1    Vanis, N.2    Mesihoviæ, R.3
  • 38
    • 0032033978 scopus 로고    scopus 로고
    • A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection
    • Trevisani L, Sartori S, Caselli M, et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1998;93:390-3.
    • (1998) Am J Gastroenterol , vol.93 , pp. 390-393
    • Trevisani, L.1    Sartori, S.2    Caselli, M.3
  • 39
    • 0029850831 scopus 로고    scopus 로고
    • Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin
    • Cammarota G, Tursi A, Papa A, et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Aliment Pharmacol Ther 1996;10:997-1000.
    • (1996) Aliment Pharmacol Ther , vol.10 , pp. 997-1000
    • Cammarota, G.1    Tursi, A.2    Papa, A.3
  • 40
    • 0033977723 scopus 로고    scopus 로고
    • Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer
    • Vcev A, Stimac D, Ivandic A, et al. Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. Aliment Pharmacol Ther 2000;14:69-72.
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 69-72
    • Vcev, A.1    Stimac, D.2    Ivandic, A.3
  • 41
    • 33748448010 scopus 로고    scopus 로고
    • Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication
    • Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;47:30-6.
    • (2006) Korean J Gastroenterol , vol.47 , pp. 30-36
    • Kang, M.S.1    Park, D.I.2    Yun, J.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.